Search

Introduction Pour evaluer l’efficacite du tocilizumab chez les patients atteints d’arterite de Takayasu (TA). Patients et methodes Nous avons realise une etude retrospective multicentrique de 46 patients avec TA traites par tocilizumab. Nous avons analyse les facteurs associes a la reponse au tocilizumab et l’incidence des complications vasculaires dans TA les patients traites avec le tocilizumab en comparaison avec ceux sous DMARDs. Resultats Quarante-six patients avec TA ont ete inclus, avec un âge mediane de 43 ans [29–54], et 35 de sexe feminin (76 %). Nous avons observe une diminution de NIH median (de 3 [2–3] au depart a 0 [0–1] et de 0 a 3 et 6 mois, respectivement ; p Conclusion Cette etude a l’echelle nationale montre que le tocilizumab est une alternative therapeutique interessante et pourrais reduire les complications vasculaires dans TA.

To report the safety and efficacy of anti-tumor necrosis factor a (TNFα) therapy in severe and refractory neuro-Behcet disease (NBD) patients. Observational, multicenter study including 17 BD patients (70.6% of male, with a median age of 39.3 [24-60] years), with symptomatic parenchymal NBD, refractory to previous immunosuppressant and treated with anti-TNFα (infliximab 5 mg/kg [n=13] or adalimumab [n=4]). Complete remission was defined by the disappearance of all neurological symptoms and by the improvement of radiological abnormalities at 12 months. Overall improvement following anti-TNF was evidenced in 16/17 (94.1%) patients including 6 (35.3%) complete response and 10 (58.8%) partial response. The median time to achieve remission was 3 months (1-6). The median Rankin score was 2 (1-4) at the initiation of anti-TNFα versus 1 (0-4) at the time of remission (P=0.01). Corticosteroids have been stopped in 4 (23.5%) patients, and reduced by more than 50% as compared with the dosage at baseline in 10 (58.8%) patients. Side effects occurred in 23.5% of patients and required treatment discontinuation in 17% of cases. TNF blockade represents an effective therapeutic approach for patients with severe and refractory NBD, a difficult to treat population.